Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198675 | 1.00 | HTR2A (0.51) | HTR2AHTR2CHTR2BTSHRALDH1A1 | |
| SCHEMBL9198668 | 1.00 | HTR2A (0.51) | HTR2AHTR2CHTR2BTSHRALDH1A1 | |
| SCHEMBL15715833 | 1.00 | HTR2A (0.51) | HTR2AHTR2CHTR2BTSHRALDH1A1 | |
| SCHEMBL9516979 | 0.85 | CYP3A4 (0.36) | HTR2AHTR2CHTR2BTSHRALDH1A1 | |
| SCHEMBL9516987 | 0.85 | CYP3A4 (0.36) | HTR2AHTR2CHTR2BTSHRALDH1A1 | |
| SCHEMBL9516996 | 0.85 | CYP3A4 (0.36) | HTR2AHTR2CHTR2BTSHRALDH1A1 | |
| SCHEMBL1982086 | 0.82 | MAPT (0.38) | HTR2AHTR2CHTR2BALDH1A1LMNA | |
| SCHEMBL8330356 | 0.82 | SLC9A1 (0.44) | HTR2AHTR2CHTR2BTSHRALDH1A1 | |
| SCHEMBL7959449 | 0.81 | TSHR (0.45) | TSHRALDH1A1SLC18A3ABCB1LMNA | |
| SCHEMBL7959447 | 0.81 | TSHR (0.45) | TSHRALDH1A1SLC18A3ABCB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522648-B1 | PROCESS FOR PRODUCING DIFLUOROCYCLOPROPANE COMPOUND | CENTRAL GLASS CO LTD (JP) | 2017-05-17 | — | — | EP | disclosed |
| US-8729320-B2 | Method for producing difluorocyclopropane compound | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| US-8729320-B2 | Method for producing difluorocyclopropane compound | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-05-20 | — | — | US | disclosed |
| EP-2522648-A1 | PROCESS FOR PRODUCING DIFLUOROCYCLOPROPANE COMPOUND | Central Glass Company, Limited (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-20120277458-A1 | METHOD FOR PRODUCING DIFLUOROCYCLOPROPANE COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-11-01 | — | — | US | disclosed |
| US-20120277458-A1 | METHOD FOR PRODUCING DIFLUOROCYCLOPROPANE COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-11-01 | — | — | US | disclosed |
| US-6291520-B1 | INHIBIT THE ENZYME LIPOXYGENASE; TREATMENT OR ALLEVIATION OF INFLAMMATORY DISEASES, ALLERGIC CONDITIONS AND CARDIOVASCULAR DISEASES | PFIZER | 2001-09-18 | — | — | US | disclosed |
| EP-0559743-B1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0436199-B1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LAB (US) | 1994-08-03 | — | — | EP | disclosed |
| EP-0559743-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE. | PFIZER HOSPITAL PROD (US) | 1993-09-15 | — | — | EP | disclosed |
| WO-1992009566-A1 | NOVEL HYDROXAMIC ACID AND N-HYDROXYUREA DERIVATIVES AND THEIR USE | PFIZER INC. (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5120752-A | N-(1-(20(3-pyridyloxy)phenyl)cyclopropyl) alkyl-N-hydroxyurea compounds, antiinflammatory agents | ABBOTT LABORATORIES (US) | 1992-06-09 | — | — | US | disclosed |
| US-5037853-A | Antiinflammatory agents | ABBOTT LABORATORIES (US) | 1991-08-06 | — | — | US | disclosed |
| EP-0436199-A1 | Cyclopropyl derivative lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1991-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277458-A1 | METHOD FOR PRODUCING DIFLUOROCYCLOPROPANE COMPOUND | FDPS, PFAS, FDFT1 | HTR2A 3410/4885HTR2C 3561/4885HTR2B 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.